# Ofatumumab in AQP4-IgG Seropositive NMOSD

> **NCT05504694** · PHASE1,PHASE2 · RECRUITING · sponsor: **Tang-Du Hospital** · enrollment: 5 (estimated)

## Conditions studied

- Neuromyelitis Optica Spectrum Disorder

## Interventions

- **DRUG:** Ofatumumab

## Key facts

- **NCT ID:** NCT05504694
- **Lead sponsor:** Tang-Du Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-28
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-07-31
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2026-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05504694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05504694, "Ofatumumab in AQP4-IgG Seropositive NMOSD". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05504694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*